文献速递白血病淋巴瘤

维莫非尼单药治疗复发或难治性毛细胞白血病患者的长期结局

Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy.
PubMed 文献 · Blood · 2022-01-01

报告美国2期临床试验(NCT01711632)中36例复发或难治性毛细胞白血病患者接受维莫非尼单药治疗的长期结局,最佳总缓解率86%,中位随访40个月,中位无复发生存期19个月,4年总生存率82%,再治疗安全有效。

要点

  • 维莫非尼治疗复发或难治性毛细胞白血病最佳总缓解率86%,完全缓解33%,部分缓解53%。
  • 中位随访40个月,31例缓解者中21例(68%)复发,中位无复发生存期19个月。
  • 再治疗14例中86%达完全血液学缓解,但12例再治疗缓解者中6例(50%)再次复发。

核心结论

  • 维莫非尼单药治疗复发或难治性毛细胞白血病再治疗是安全有效的选择。

研究设计与样本

  • 美国2期临床试验(NCT01711632)美国研究组,纳入36例复发或难治性毛细胞白血病患者接受维莫非尼单药治疗。

主要发现

  • 最佳总缓解率86%,其中完全缓解33%、部分缓解53%。
  • 中位随访40个月,31例缓解者中21例(68%)复发,中位无复发生存期19个月(范围12.5-53.9个月)。
  • 完全缓解与部分缓解患者的无复发生存期无显著差异。
  • 21例复发患者中14例(67%)接受维莫非尼再治疗,86%达完全血液学缓解。
  • 2例患者分别出现新的KRAS和CDKN2A突变获得维莫非尼耐药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vemurafenib, an oral BRAF inhibitor, has demonstrated high response rates in relapsed/refractory (R/R) hairy cell leukemia (HCL). However, little is known about long-term outcomes and response to retreatment. Herein, we report the results of 36 patients with R/R HCL treated with vemurafenib from the United States arm of the phase 2 clinical trial (NCT01711632). The best overall response rate was 86%, including 33% complete response (CR) and 53% partial response (PR). After a median follow-up of 40 months, 21 of 31 responders (68%) experienced relapse with a median relapse-free survival (RFS) of 19 months (range, 12.5-53.9 months). There was no significant difference in the RFS for patients with CR vs PR. Fourteen of 21 (67%) relapsed patients were retreated with vemurafenib, with 86% achieving complete hematologic response. Two patients acquired resistance to vemurafenib with the emergence of new KRAS and CDKN2A mutations, respectively. Six of 12 (50%) responders to vemurafenib retreatment experienced another relapse with a median RFS of 12.7 months. Overall survival (OS) was 82% at 4 years, with a significantly shorter OS in patients who relapsed within 1 year of initial treatment with vemurafenib. Higher cumulative doses or a longer duration of treatment did not lengthen the durability of response. All adverse events in the retreatment cohort were grade 1/2 except for 1 case of a grade 3 rash and 1 grade 3 fever/pneumonia. Our data suggest that vemurafenib retreatment is a safe and effective option for patients with R/R HCL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Handa S, Lee JO, Derkach A, et al. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022. PMID: 35930750. doi:10.1182/blood.2022016183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。